Assertio Therapeutics

Last updated
Assertio Therapeutics, Inc.
Company type Public
Nasdaq:  ASRT
Industry Pharmaceutical
Founded1995;30 years ago (1995)
Headquarters Newark, California
Key people
Dan A. Peisert (CEO) [1]
ProductsPharmaceuticals
RevenueDecrease2.svgUS$57.2 million (2019) [2]
Increase2.svgUS$3.33 million (2019) [2]
Decrease2.svgUS$-13.6 million (2019) [2]
Number of employees
116 (2019) [1]
Website www.assertiotx.com

Assertio Therapeutics, Inc. (formerly Depomed, Inc.) is an American specialty pharmaceutical company. [3] It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. [4] Depomed was founded in 1995 and is headquartered in Newark, California. [5] It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. [6] As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor. [7]

Contents

History

1995-2009

Depomed was founded in 1995 [3] and later became headquartered in Newark, California. [5] A joint venture between Élan and Depomed, DDL, was established in January 2000. Élan withdrew from operational involvement in September 2003, with Depomed gaining full ownership. [8] In September 2003, the company's subsidiary Depomed Development Ltd. acquired the exclusive rights to develop and commercialize Gabapentin ER. The drug had been developed by DDL. [8] 2003 saw a net loss of $30 million, compared to $13.5 million in 2002. [9] In 2004, John W. Fara was president, CEO, and chairman. [9] The company had 75 people, and was starting a new focus on marketing after FDA approvals for Proquin XR and Depomed's filing of Glumetza for approval. [3] By May 2004, Depomed had been issued a patent covering the use of gabapentin to treat hot flushes. That month, it also received a patent covering "proprietary polymer combinations (as used in AcuForm tablets) to create improved formulations of existing drugs." [8] The patent was first sublicensed to the University of Rochester, then PharmaNova in October 2006. [8] The company faced a net loss of $24.5 million in 2005, compared to a net loss of $27 million in 2004. [10]

In April 2006, Depomed entered a license agreement with Esprit Pharma over Proquin XR, a "prolonged-release formulation of ciprofloxacin hydrochloride" to treat urinary tract infections. [11] In July 2008, the FDA released a warning about drugs such as Depomed Inc's Proquin XR, an antibiotic, about the risk of tendonitis and ruptured tendons. [12]

2010-2014

By 2010 the company was based in Menlo Park, California, and stated it intended to become profitable in 2011. [13] By 2010, Depomed was supplying its entire logistics system with plastic pallets, after it had to recall a shipment of the diabetes drug Glumetza for potential contamination of wood pallets. [14] As of March 2011, Carl A. Pelzel was CEO and president of Depomed. Depomed had one approved product on the market, Gralise, and had one other approved but not released: Glumetza. [15] That month, Boehringer Ingelheim purchased the rights to use Depomed's Acuform manufacturing technology. [15] The FDA approved Gralise for the management of postherpetic neralgia in January 2012. [16]

On June 21, 2012, Depomed acquired the rights to Zipsor, an NSAID made by Xanodyne Pharmaceuticals. [17] In particular, the Zipsor Liquid Filled Capsules were acquired. Revenue generated by Zipsor was approximately US$ 19,000,000 as within the twelve months from June 2011 to May 2012. [18] For $240 million, DL BioPharma purchased the royalty rights to Depomed's Glumetza, a type 2 diabetes drug, in October 2013. The year prior, Depomed had generated $43 million in royalty revenue off the drug. [19]

2015-2017

In January 2015, [20] Depomed acquired Nucynta ER and XR from Johnson & Johnson for $1.05 billion. [21] Horizon Pharma made a hostile $3 billion bid for Depomed in July 2015, [20] withdrawing the bid after the Depomed board rejected the offer. [22] At the time, Depomed had five pain treatments on the market, including Nucynta, considered its flagship product. [20] Assets in 2015 came to $1.3 billion. Equity that year was $315 million, [2] and it had 494 employees that December. [23]

In early April 2016, activist investor Starboard Value accused DepoMed of being "unfriendly to shareholders," noting in part a plan to relocate from California to Delaware. Several weeks later, the Delaware move was dropped. [24] In September 2016, there were reports that Depomed was considering a sale, after Starboard called for the option to be explored in April 2016. [25] In October 2016, Starboard Value struck a deal with Depomed that gave the former three more spots on Depomed's board. In March 2017, more activity by activist investors resulted in CEO Jim Schoeneck being replaced by Arthur Higgins. [21] In December 2017, Depomed announced it was moving away from the opioid market and divesting of its Nucynta opioid franchise. [26] Nucynta's rights were sold to Collegium Pharmaceutical, for $10 million upfront and royalty payments until December 2022. [27] That year, Depomed's net revenue was $381 million. [22] [20]

2018-2019

In January 2018 the company laid off 40% of its workforce after the divestment of its pain medication Nucynta. [21] On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. [6] In 2018, Assertio also moved its headquarters from California to Lake Forest, [27] from Newark, California to Lake Forest, Illinois. [22]

By March 2019, Assertio's stock had lost half its value since 2016. [28] In September 2019, Crain's Chicago Business argued that Assertio's diversification campaign was "sputtering", with Assertio stock having dropped 80% in the prior year. [27] Operating income in 2019 was $3.33 million. [2] Becker's Hospital Review listed it as one of 31 drugmakers at high risk of going bankrupt in 2020. [29]

Products and manufacturing

By 2010 the company was based in Menlo Park, California, and was known for improving "the bio-availability of generic drugs by using polymers usually used in the food and cosmetics industry to reduce side effects and lower the doses necessary for oral medications." [13] As of 2019, Assertio markets three products approved by the FDA: Gralise, Cambia, and Zipsor. [7] The company's products include Gralise, Cambia, Lazanda, Zipsor, and DM-1992, which mainly focus on pain, neuropathic pain, and central nervous system diseases. [4]

In January 2011, Gralise once-daily (gabapentin extended release) was approved by the US FDA for the treatment of postherpetic neuralgia. [30] The drug has also received Orphan Drug designation from the FDA.

The company's diabetes treatment, Glumetza (metformin hydrochloride extended release tablet), was approved for the treatment of type II diabetes in adults, and is sold in the US by Valeant. [31]

Former products

Assertio Therapeutics previously owned Nucynta ER and Nucynta IR. On January 15, 2015, Depomed announced the acquisition of the Tapentadol(Nucynta) franchise from Janssen Pharmaceutica for US$ 1,050,000,000 in cash. The transaction closed on April 2, 2015, and the products were relaunched in June 2015 after a major sales force expansion. After Hurricane Maria in 2017 the company faced major shortages of the drug due to the manufacturing plant location in Puerto Rico. [32] In January 2018, after less than 3 years, the manufacturing rights of Nucynta were sold for just $10 million upfront with a $135 million in royalties for the first 4 years. [21] Tapentadol is now produced for the US and Canadian market by Collegium Pharmaceutical. [21]

Lawsuits

The company has been active in patent litigation. In 2002, the company received $18 million from the Bristol-Myers Squibb Company concerning a patent litigation settlement. [9] In April 2008, Depomed sued IVAX for introducing a generic Glumetza product, forcing IVAX's owner Teva Pharmaceutical Industries into paying a $7.5 million settlement on the matter. [13] By May 2010, Depomed also had had patient victories against Viovail Corporation. [13]

In March 2012, the company filed a patent infringement lawsuit against three companies that had filed Abbreviated New Drug Applications with the US FDA, claiming infringement of Depomed's six US patents listed for Gralise in the FDA's Orange Book. [33] In August 2018, Purdue Pharma paid Assertio $62 million to settle a patent infringement lawsuit. The suit had been filed in 2013, alleging Purdue infringed on certain patents relating to OxyContin. [34]

The company has faced a number of lawsuits related to its marketing of the Nucynta opioid painkiller, with Assertio denying wrongdoing. [27] In January 2019, an insurer had asked California federal courts if it had to cover Assertio's defense in opioid-related cases filed in approximately 38 different cases in 2018. [35] In March 2019, Assertio won a dismissal of a lawsuit by shareholders that accused the company of hiding how much its growth was dependent on Nucynta marketing for off-label purposes. According to the judge, the plaintiffs failed to provide evidence of a scheme. [36]

See also

Related Research Articles

<span class="mw-page-title-main">Novartis</span> Swiss multinational pharmaceutical corporation

Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical companies in the world and was the fourth largest by revenue in 2022.

An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance compared to their performance at the time when they were patented drugs. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

<span class="mw-page-title-main">Takeda Pharmaceutical Company</span> Japanese pharmaceutical company

The Takeda Pharmaceutical Company Limited is a Japanese multinational pharmaceutical company. It is the third largest pharmaceutical company in Asia, behind Sinopharm and Shanghai Pharmaceuticals, and one of the top 20 largest pharmaceutical companies in the world by revenue. The company has over 49,578 employees worldwide and achieved US$19.299 billion in revenue during the 2018 fiscal year. The company is focused on oncology, rare diseases, neuroscience, gastroenterology, plasma-derived therapies and vaccines. Its headquarters is located in Chuo-ku, Osaka, and it has an office in Nihonbashi, Chuo, Tokyo. In January 2012, Fortune Magazine ranked the Takeda Oncology Company as one of the 100 best companies to work for in the United States. As of 2015, Christophe Weber was appointed as the CEO and president of Takeda.

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

Shire plc was a UK-founded Jersey-registered specialty biopharmaceutical company. Originating in the United Kingdom with an operational base in the United States, its brands and products included Vyvanse, Lialda, and Adderall XR. Shire was acquired by Takeda Pharmaceutical Company on 8 January 2019.

<span class="mw-page-title-main">Amgen</span> American multinational biopharmaceutical company

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. As one of the world's largest independent biotechnology companies, Amgen has approximately 24,000 staff in total as of 2022.

<span class="mw-page-title-main">Dr. Reddy's Laboratories</span> Indian multinational pharmaceutical company

Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients (APIs) for drug manufacture, diagnostic kits, critical care, and biotechnology.

<span class="mw-page-title-main">Celgene</span> American biopharmaceutical company

Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).

<span class="mw-page-title-main">Astellas Pharma</span> Japanese pharmaceutical company

Astellas Pharma Inc. is a Japanese multinational pharmaceutical company, formed on 1 April 2005 from the merger of Yamanouchi Pharmaceutical Co., Ltd. and Fujisawa Pharmaceutical Co., Ltd..

<span class="mw-page-title-main">Teva Pharmaceuticals</span> Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.

<span class="mw-page-title-main">Mallinckrodt</span> Irish domiciled pharmaceutical

Mallinckrodt Pharmaceuticals plc is an American-Irish domiciled manufacturer of specialty pharmaceuticals, generic drugs and imaging agents. In 2017, it generated 90% of its sales from the U.S. healthcare system. While Mallinckrodt is headquartered in Ireland for tax purposes, its operational headquarters are in the U.S. Mallinckrodt's 2013 tax inversion to Ireland drew controversy when it was shown Acthar was Medicaid's most expensive drug.

<span class="mw-page-title-main">Omega-3-acid ethyl esters</span> Pharmaceutical product

Omega-3-acid ethyl esters are a mixture of ethyl eicosapentaenoic acid and ethyl docosahexaenoic acid, which are ethyl esters of the omega−3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) found in fish oil. Together with dietary changes, they are used to treat high blood triglycerides which may reduce the risk of pancreatitis. They are generally less preferred than statins, and use is not recommended by NHS Scotland as the evidence does not support a decreased risk of heart disease. Omega-3-acid ethyl esters are taken by mouth.

Spectrum Pharmaceuticals, Inc. is an American biopharmaceutical company located in Boston, MA. It develops and markets drugs for treatments in hematology and oncology.

<span class="mw-page-title-main">AbbVie</span> American pharmaceutical company

AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. It is ranked sixth on the list of largest biomedical companies by revenue. In 2023, the company's seat in Forbes Global 2000 was 74, and rank 89 on the 2024 list. The company's primary product is Humira (adalimumab), administered via injection. It is approved to treat autoimmune diseases including rheumatoid arthritis, Crohn's disease, plaque psoriasis, and ulcerative colitis.

Orexo is a Swedish pharmaceutical company that develops improved pharmaceuticals based on innovative formulation technologies that meet large medical needs. Through presence its in the US market, drugs and digital therapies are commercialized to treat opioid use disorder and adjacent diseases. Products targeting other therapeutic areas are developed and commercialized worldwide with partners.

Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem, the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals.

Horizon Therapeutics plc was a biopharmaceutical company focused on researching, developing, and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. Horizon primarily markets products in the United States, which represented 97% of Horizon's 2019 worldwide sales. Amgen acquired the company in October 2023.

Allergan plc is an American, Irish-domiciled pharmaceutical company that acquires, develops, manufactures and markets brand name drugs and medical devices in the areas of medical aesthetics, eye care, central nervous system, and gastroenterology. The company is the maker of Botox.

Pronova BioPharma is a Norwegian company. In Denmark it is a bulk manufacturer of omega-3 products with a manufacturing plant in Kalundborg. It was acquired by BASF in 2014.

References

  1. 1 2 Assertio Therapeutics Inc, Bloomberg , retrieved November 20, 2019
  2. 1 2 3 4 5 "DEPO Income Statement". Yahoo Finance. Retrieved 16 January 2017.
  3. 1 2 3 Levine, Daniel S. (September 26, 2004), Drugmaker Depomed takes shot at billions, San Francisco Business Times , retrieved November 25, 2019
  4. 1 2 "Depomed Inc: NASDAQ:DEPO quotes & news". Google Finance. Archived from the original on December 20, 2013. Retrieved Jan 29, 2014.
  5. 1 2 "DEPO Profile | Depomed, Inc. Stock". Yahoo! Finance. Retrieved Jan 2, 2016.
  6. 1 2 Globe Newswire, CNBC, August 15, 2018, archived from the original on January 21, 2019, retrieved November 20, 2019
  7. 1 2 Marketed Products, Assertio, 2019, retrieved November 25, 2019
  8. 1 2 3 4 "Gabapentin Extended-Release - Depomed: Gabapentin ER, Gabapentin Gastric Retention, Gabapentin GR.", Drugs in R&D, 8 (5), Drugs R. D.: 317–20, 2007, doi:10.2165/00126839-200708050-00005, PMID   17767396, S2CID   195340176
  9. 1 2 3 Depomed Reports 2003 Year End Financial Results, DepoMed, March 3, 2004, retrieved November 25, 2019
  10. ↑ Depomed, Inc. Reports 2005 Year End Financial Results, BioSpace / Business Wire, March 14, 2006, retrieved November 25, 2019
  11. ↑ Holmberg, Monica (April 1, 2006), Depomed and Esprit Pharma's Proquin XR, Pharmacy Times, retrieved November 25, 2019
  12. ↑ Heavey, Susan (July 8, 2008), Antibiotics can harm tendons, FDA warns, Reuters , retrieved November 25, 2019
  13. 1 2 3 4 Kam, Ken (May 21, 2010), "Special Delivery From Depomed", Forbes , retrieved November 25, 2019
  14. ↑ Edwards, Jim (November 3, 2010), "How the Humble Wooden Pallet Paralyzed Big Pharma and Now Faces Extinction", CBS News , retrieved November 25, 2019
  15. 1 2 Depomed Licenses Acuform(R) Technology and Glumetza(R) Data to Boehringer Ingelheim, Fierce Biotech, March 16, 2011, archived from the original on August 5, 2021, retrieved November 25, 2019
  16. ↑ Holmberg, Monica (January 9, 2012), New FDA Actions: Depomed Inc's Gralise, January 2012 Aging Population, vol. 78, Pharmacy Times, retrieved November 25, 2019
  17. ↑ Depomed Announces Acquisition Of Zipsor® (diclofenac potassium) From Xanodyne Pharmaceuticals, Inc., Depomed, June 21, 2012, retrieved November 25, 2019
  18. ↑ "Depomed Announces Acquisition Of Zipsor® (diclofenac potassium) From Xanodyne Pharmaceuticals, Inc" (Press release). Depomed. Jun 21, 2012. Retrieved Feb 5, 2014– via PRNewswire.
  19. ↑ Leuty, Ron (October 21, 2013), PDL grabs royalties, Depomed gets cash in diabetes drug deal, San Francisco Business Times , retrieved November 25, 2019
  20. 1 2 3 4 Nathan, Vidya L. (July 7, 2015), Horizon Pharma goes hostile with $3 billion offer for Depomed, Reuters , retrieved November 20, 2019
  21. 1 2 3 4 5 "Troubled Depomed sells off Nucynta, axes 40% of workforce to pare down costs". FiercePharma. Retrieved 2019-10-15.
  22. 1 2 3 Liu, Evonne (March 20, 2018), Lake Forest pharma complex attracts another HQ, Crain's Chicago Business , retrieved November 25, 2019
  23. ↑ Results in 2015, depomedinc.co, 2015, retrieved November 20, 2019[ dead link ]
  24. ↑ J. de la Merced, Michael (April 28, 2016), "Starboard Value's Rise to Activist Prominence", The New York Times , retrieved November 20, 2019
  25. ↑ Roumeliotis, Greg (September 15, 2016), Exclusive: Drugmaker Depomed prepares to explore a sale - sources, Reuters , retrieved November 20, 2019
  26. ↑ Helfand, Carly (August 15, 2018), Depomed joins ranks of scandal-plagued pharmas rehabbing their reputations with a name change, FiercePharma, retrieved November 20, 2019
  27. 1 2 3 4 Goldberg, Stephanie (September 6, 2019), Opioid habit hangs on at Lake Forest drugmaker, Crain's Chicago Business , retrieved November 20, 2019
  28. ↑ Herbst-Bayliss, Svea (March 29, 2019), Starboard abandons campaign to scuttle Bristol-Myers-Celgene deal , retrieved November 25, 2019
  29. ↑ Anderson, Maia (November 20, 2019), 31 drugmakers at high risk for bankruptcy in 2020, Beckers Hospital Review, retrieved November 20, 2019
  30. ↑ "Depomed Announces US Food and Drug Administration Approval of GRALISE(TM) (gabapentin) Once-Daily Tablets for Treatment of Post-Herpetic Neuralgia" (Press release). Depomed. Jan 28, 2011. Archived from the original on February 5, 2014. Retrieved Feb 5, 2014.
  31. ↑ "Depomed Inc (DEPO.O) Company Profile". Reuters. Archived from the original on October 22, 2008. Retrieved Feb 5, 2014.
  32. ↑ RPh, Meaghan Byrne, PharmD , CPE & Frank Pallaria. "Dealing with Prescription Drug Shortages". www.iwpharmacy.com. Retrieved 2019-10-15.{{cite web}}: CS1 maint: multiple names: authors list (link)
  33. ↑ "Depomed Files Patent Infringement Lawsuit Against Gralise(R) ANDA Filers" (Press release). Depomed. Mar 5, 2012. Retrieved Jan 2, 2016– via Globe Newswire (NASDAQ).
  34. ↑ Zimmerman, Kevin (August 30, 2018), Purdue Pharma settles patent infringement suit over OxyContin for $62M , retrieved November 20, 2019
  35. ↑ Insurers Seek to Avoid Being Drawn Into Opioid Litigation, Bloomberg, January 17, 2019, retrieved November 20, 2019
  36. ↑ Raymond, Nate (March 19, 2019), Assertio Therapeutics beats investor lawsuit over opioid marketing, Reuters , retrieved November 20, 2019
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.